Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cell therapies
- Indications Mesothelioma
- Focus Adverse reactions
Most Recent Events
- 19 Sep 2017 Biomarkers information updated
- 17 Sep 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov record.
- 17 Sep 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.